Prot #VS-6766-202: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

Project: Research project

Project Details

StatusActive
Effective start/end date5/21/215/21/24

Funding

  • Parexel (Prot #VS-6766-202)
  • Verastem, Inc. (Prot #VS-6766-202)